No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.04M | 889K | 837K | 3M | 0 | 10M | 3M | 1.41M | 3.5M | 0 |
| Revenue Growth % | 0.12% | -0.15% | -0.06% | 2.58% | -1% | - | -0.7% | -0.53% | 1.48% | -1% |
| Cost of Goods Sold | 0 | 10.65M | 16.99M | 38.7M | 48.57M | 0 | 0 | 450K | 1.6M | 2.91M |
| COGS % of Revenue | - | 11.99% | 20.3% | 12.91% | - | - | - | 0.32% | 0.46% | - |
| Gross Profit | 1.04M | -9.77M | -16.15M | -35.7M | -48.57M | 10M | 3M | 964K | 1.9M | -2.91M |
| Gross Margin % | 1% | -10.99% | -19.3% | -11.91% | - | 1% | 1% | 0.68% | 0.54% | - |
| Gross Profit Growth % | 0.12% | -10.39% | -0.65% | -1.21% | -0.36% | 1.21% | -0.7% | -0.68% | 0.97% | -2.53% |
| Operating Expenses | 19.59M | 24.77M | 28.67M | 61.16M | 28.52M | 91.42M | 92.84M | 51.88M | 49.03M | 61.3M |
| OpEx % of Revenue | 18.83% | 27.86% | 34.26% | 20.4% | - | 9.14% | 30.95% | 36.69% | 14.01% | - |
| Selling, General & Admin | 14.32M | 13.29M | 10.94M | 20.11M | 20.7M | 23.78M | 21.64M | 17.26M | 19M | 29.85M |
| SG&A % of Revenue | 13.77% | 14.95% | 13.07% | 6.71% | - | 2.38% | 7.21% | 12.2% | 5.43% | - |
| Research & Development | 4.71M | 10.65M | 16.99M | 38.7M | 53.77M | 30.14M | 38.73M | 28.96M | 31.09M | 34.36M |
| R&D % of Revenue | 4.53% | 11.99% | 20.3% | 12.91% | - | 3.01% | 12.91% | 20.48% | 8.88% | - |
| Other Operating Expenses | 551K | 825K | 741K | 2.36M | -45.95M | 37.5M | 32.47M | 5.66M | -1.06M | -2.91M |
| Operating Income | -18.55M | -23.88M | -27.84M | -58.17M | -77.09M | -81.42M | -89.84M | -50.91M | -47.13M | -64.21M |
| Operating Margin % | -17.83% | -26.86% | -33.26% | -19.4% | - | -8.14% | -29.95% | -36.01% | -13.47% | - |
| Operating Income Growth % | -4.92% | -0.29% | -0.17% | -1.09% | -0.33% | -0.06% | -0.1% | 0.43% | 0.07% | -0.36% |
| EBITDA | -18M | -23.06M | -27.09M | -55.81M | -69.27M | -75.82M | -85.37M | -46.34M | -43.94M | -61.3M |
| EBITDA Margin % | -17.3% | -25.93% | -32.37% | -18.61% | - | -7.58% | -28.46% | -32.77% | -12.55% | - |
| EBITDA Growth % | -4.77% | -0.28% | -0.18% | -1.06% | -0.24% | -0.09% | -0.13% | 0.46% | 0.05% | -0.4% |
| D&A (Non-Cash Add-back) | 551K | 825K | 741K | 2.36M | 7.82M | 5.6M | 4.46M | 4.58M | 3.2M | 2.91M |
| EBIT | -14.52M | -21.87M | -27.32M | -56.67M | -77.09M | -80.12M | -81.28M | -38.96M | -53.77M | -59.53M |
| Net Interest Income | 4.02M | 2.01M | 517K | 1.5M | 808K | -2.81M | -3.62M | -305K | 1.7M | 38K |
| Interest Income | 4.03M | 2.01M | 525K | 1.51M | 1.21M | 1.3M | 40K | 431K | 2.12M | 4.25M |
| Interest Expense | 6K | 6K | 8K | 11K | 400K | 4.12M | 3.66M | 736K | 418K | 4.21M |
| Other Income/Expense | 4.02M | 2.01M | 517K | 1.5M | 808K | -2.81M | 4.9M | 11.22M | -7.05M | 477K |
| Pretax Income | -14.53M | -21.87M | -27.32M | -56.67M | -76.28M | -84.23M | -84.94M | -39.7M | -54.19M | -63.73M |
| Pretax Margin % | -13.97% | -24.6% | -32.64% | -18.9% | - | -8.42% | -28.31% | -28.07% | -15.48% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -14.53M | -21.87M | -27.32M | -56.67M | -76.28M | -84.23M | -84.94M | -39.7M | -54.19M | -63.73M |
| Net Margin % | -13.97% | -24.6% | -32.64% | -18.9% | - | -8.42% | -28.31% | -28.07% | -15.48% | - |
| Net Income Growth % | 0.46% | -0.51% | -0.25% | -1.07% | -0.35% | -0.1% | -0.01% | 0.53% | -0.37% | -0.18% |
| Net Income (Continuing) | -14.53M | -21.87M | -27.32M | -56.67M | -76.28M | -84.23M | -84.94M | -39.7M | -54.19M | -63.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -13.16 | -16.00 | -16.40 | -29.81 | -38.07 | -22.75 | -21.50 | -5.53 | -2.53 | -1.55 |
| EPS Growth % | 0.97% | -0.22% | -0.03% | -0.82% | -0.28% | 0.4% | 0.05% | 0.74% | 0.54% | 0.39% |
| EPS (Basic) | -13.16 | -16.00 | -16.40 | -29.81 | -38.07 | -22.75 | -21.50 | -5.53 | -2.53 | -1.55 |
| Diluted Shares Outstanding | 1.1M | 1.37M | 1.67M | 1.9M | 2.01M | 3.71M | 3.94M | 7.86M | 21.38M | 41.05M |
| Basic Shares Outstanding | 1.1M | 1.37M | 1.67M | 1.9M | 2.01M | 3.71M | 3.94M | 7.86M | 21.38M | 41.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 40.57M | 69.42M | 140.59M | 88.85M | 132.39M | 97.74M | 56.29M | 53.1M | 55.74M | 100.85M |
| Cash & Short-Term Investments | 40.14M | 69.14M | 137.75M | 84.97M | 129.26M | 95.03M | 45.02M | 52.15M | 52.23M | 97.72M |
| Cash Only | 40.14M | 69.14M | 137.75M | 18.75M | 129.26M | 12.6M | 32.94M | 14.22M | 14.47M | 23.36M |
| Short-Term Investments | 0 | 0 | 0 | 66.22M | 0 | 82.44M | 12.09M | 37.93M | 37.75M | 74.36M |
| Accounts Receivable | 115K | 124K | 107K | 81K | 0 | 0 | 3M | 188K | 2.44M | 1.65M |
| Days Sales Outstanding | 40.36 | 50.91 | 46.66 | 9.86 | - | - | 365 | 48.53 | 254.87 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 891K | 762K | 338K | 1.48M |
| Total Non-Current Assets | 39.49M | 41.64M | 38.17M | 85.55M | 90.99M | 53.46M | 23.29M | 11.12M | 8.27M | 8.08M |
| Property, Plant & Equipment | 350K | 721K | 1.37M | 9.44M | 21.2M | 18.35M | 21.74M | 11.07M | 7.99M | 7.98M |
| Fixed Asset Turnover | 2.97x | 1.23x | 0.61x | 0.32x | - | 0.54x | 0.14x | 0.13x | 0.44x | - |
| Goodwill | 32.47M | 32.47M | 32.47M | 32.47M | 32.47M | 32.47M | 0 | 0 | 0 | 0 |
| Intangible Assets | 6.61M | 8.38M | 3.98M | 43.04M | 36.18M | 1.5M | 1.38M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 62K | 66K | 357K | 597K | 1.14M | 1.14M | 168K | 43K | 277K | 96K |
| Total Assets | 80.06M | 111.06M | 178.77M | 174.4M | 223.38M | 151.2M | 79.59M | 64.21M | 64M | 108.93M |
| Asset Turnover | 0.01x | 0.01x | 0.00x | 0.02x | - | 0.07x | 0.04x | 0.02x | 0.05x | - |
| Asset Growth % | 3.83% | 0.39% | 0.61% | -0.02% | 0.28% | -0.32% | -0.47% | -0.19% | -0% | 0.7% |
| Total Current Liabilities | 1.48M | 8.3M | 5.61M | 20.35M | 38.7M | 41.96M | 16.62M | 7.78M | 13.42M | 16.59M |
| Accounts Payable | 875K | 3.69M | 1.88M | 6.12M | 3.76M | 4.7M | 4.33M | 1.81M | 1.86M | 3.44M |
| Days Payables Outstanding | - | 126.54 | 40.41 | 57.74 | 28.28 | - | - | 1.47K | 422.54 | 432.05 |
| Short-Term Debt | 0 | 0 | 0 | 10M | 0 | 330K | 0 | 0 | 0 | 5.93M |
| Deferred Revenue (Current) | 602K | 602K | 1000K | 296K | 296K | 296K | 296K | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | -10M | 0 | 0 | 1.79M | 2.8M | 3.69M | 4.46M |
| Current Ratio | 27.47x | 8.37x | 25.07x | 4.37x | 3.42x | 2.33x | 3.39x | 6.83x | 4.15x | 6.08x |
| Quick Ratio | 27.47x | 8.37x | 25.07x | 4.37x | 3.42x | 2.33x | 3.39x | 6.83x | 4.15x | 6.08x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 10.86M | 3.66M | 3.06M | 20M | 6.25M | 6.69M | 20.59M | 29.67M | 35.75M | 48.31M |
| Long-Term Debt | 4M | 0 | 0 | 20M | 0 | 1.43M | 0 | 0 | 0 | 13.04M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 6.25M | 5.26M | 7.56M | 5.85M | 4.4M | 3.26M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.59M | 0 | 0 | 0 | 0 | 0 | 13.04M | 23.82M | 31.35M | 32.01M |
| Total Liabilities | 12.33M | 11.96M | 8.67M | 40.35M | 44.95M | 48.65M | 37.22M | 37.45M | 49.18M | 64.9M |
| Total Debt | 4M | 0 | 0 | 30M | 7.95M | 8.73M | 9.38M | 7.63M | 5.4M | 23.05M |
| Net Debt | -36.14M | -69.14M | -137.75M | 11.25M | -121.31M | -3.87M | -23.56M | -6.59M | -9.07M | -309K |
| Debt / Equity | 0.06x | - | - | 0.22x | 0.04x | 0.09x | 0.22x | 0.29x | 0.36x | 0.52x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -3091.00x | -3980.17x | -3479.50x | -5287.82x | -192.73x | -19.79x | -24.57x | -69.18x | -112.76x | -15.26x |
| Total Equity | 67.72M | 99.1M | 170.1M | 134.04M | 178.43M | 102.55M | 42.37M | 26.76M | 14.83M | 44.03M |
| Equity Growth % | 13.06% | 0.46% | 0.72% | -0.21% | 0.33% | -0.43% | -0.59% | -0.37% | -0.45% | 1.97% |
| Book Value per Share | 61.34 | 72.49 | 102.16 | 70.51 | 88.59 | 27.66 | 10.76 | 3.40 | 0.69 | 1.07 |
| Total Shareholders' Equity | 67.72M | 99.1M | 170.1M | 134.04M | 178.43M | 102.55M | 42.37M | 26.76M | 14.83M | 44.03M |
| Common Stock | 328K | 403K | 469K | 479K | 836K | 961K | 1.47M | 177K | 265K | 457K |
| Retained Earnings | -310.6M | -332.47M | -359.79M | -410.19M | -486.47M | -570.7M | -655.64M | -695.34M | -749.52M | -813.26M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | -10K | -27K | -129K | -66K | 8K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.42M | -13.01M | -22.93M | -39.11M | -62.82M | -35.02M | -65.67M | -43.48M | -37.01M | -56.02M |
| Operating CF Margin % | -10.02% | -14.64% | -27.4% | -13.05% | - | -3.5% | -21.89% | -30.75% | -10.57% | - |
| Operating CF Growth % | -5.47% | -0.25% | -0.76% | -0.71% | -0.61% | 0.44% | -0.88% | 0.34% | 0.15% | -0.51% |
| Net Income | -14.53M | -21.87M | -27.32M | -56.67M | -76.28M | -84.23M | -84.94M | -39.7M | -54.19M | -63.73M |
| Depreciation & Amortization | 551K | 825K | 741K | 2.36M | 8.68M | 5.6M | 4.46M | 4.58M | 3.2M | 2.91M |
| Stock-Based Compensation | 4.37M | 4.83M | 5.92M | 8.87M | 8.24M | 8.19M | 8.92M | 3.05M | 4.77M | 6.63M |
| Deferred Taxes | 0 | 0 | -1.4M | -1.31M | 0 | 32.92M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.25M | 3.43M | 1.27M | 688K | 101K | 877K | 24.15M | -5.52M | 11M | 2.57M |
| Working Capital Changes | -6.07M | -227K | -2.15M | 6.96M | -3.55M | 1.63M | -18.26M | -5.89M | -1.79M | -4.38M |
| Change in Receivables | -79K | -9K | 17K | 26K | 81K | 0 | -3M | 2.81M | 0 | 792K |
| Change in Inventory | -316K | 156K | -2.58M | -1.03M | -81K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.17M | 2.82M | -1.3M | 7.67M | -1.71M | -2.18M | -15.59M | -9.11M | 2.04M | -3.49M |
| Cash from Investing | 3.39M | -519K | -860K | -85.09M | 59.98M | -83.71M | 66.06M | -23.96M | 208K | -39.24M |
| Capital Expenditures | -308K | -519K | -860K | -19.49M | -6.51M | -1.34M | -4.15M | -130K | -331K | -2.45M |
| CapEx % of Revenue | 0.3% | 0.58% | 1.03% | 6.5% | - | 0.13% | 1.38% | 0.09% | 0.09% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -19.49M | 0 | -1.34M | 0 | 1.73M | 204K | 18K |
| Cash from Financing | 35.65M | 42.54M | 92.4M | 5.48M | 113.9M | 1.94M | 24.86M | 43.17M | 37.06M | 104.14M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -400K | 350K | 6.23M | 0 | 969K | 177K | 831K | -5K | -332K | -1.49M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -10.73M | -13.53M | -23.8M | -58.6M | -69.33M | -36.35M | -69.82M | -43.61M | -37.34M | -58.46M |
| FCF Margin % | -10.32% | -15.22% | -28.43% | -19.55% | - | -3.64% | -23.27% | -30.84% | -10.67% | - |
| FCF Growth % | -5.66% | -0.26% | -0.76% | -1.46% | -0.18% | 0.48% | -0.92% | 0.38% | 0.14% | -0.57% |
| FCF per Share | -9.72 | -9.90 | -14.29 | -30.83 | -34.42 | -9.81 | -17.73 | -5.55 | -1.75 | -1.42 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.59x | 0.84x | 0.69x | 0.82x | 0.42x | 0.77x | 1.10x | 0.68x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.67M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14K | 7K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -40.05% | -26.22% | -20.3% | -37.27% | -48.82% | -59.96% | -117.22% | -114.85% | -260.6% | -216.57% |
| Return on Invested Capital (ROIC) | -95.01% | -58.21% | -67.02% | -49.11% | -57.13% | -78.38% | -114.69% | -195.93% | -272.73% | -194.68% |
| Gross Margin | 100% | -1098.54% | -1929.75% | -1190.79% | - | 100% | 100% | 68.18% | 54.14% | - |
| Net Margin | -1396.73% | -2460.4% | -3263.92% | -1890.29% | - | -842.34% | -2831.2% | -2807.36% | -1548.23% | - |
| Debt / Equity | 0.06x | - | - | 0.22x | 0.04x | 0.09x | 0.22x | 0.29x | 0.36x | 0.52x |
| Interest Coverage | -3091.00x | -3980.17x | -3479.50x | -5287.82x | -192.73x | -19.79x | -24.57x | -69.18x | -112.76x | -15.26x |
| FCF Conversion | 0.72x | 0.59x | 0.84x | 0.69x | 0.82x | 0.42x | 0.77x | 1.10x | 0.68x | 0.88x |
| Revenue Growth | 12.43% | -14.52% | -5.85% | 258.18% | -100% | - | -70% | -52.87% | 147.52% | -100% |
| 2018 | 2020 | 2021 | |
|---|---|---|---|
| License and Other Revenues | - | 10M | 3M |
| License and Other Revenues Growth | - | - | -70.00% |
| Foundation | 5.71M | - | - |
| Foundation Growth | - | - | - |
| License | 602K | - | - |
| License Growth | - | - | - |
Abeona Therapeutics Inc. (ABEO) reported $0.4M in revenue for fiscal year 2024. This represents a 78% decrease from $1.8M in 2011.
Abeona Therapeutics Inc. (ABEO) saw revenue decline by 100.0% over the past year.
Yes, Abeona Therapeutics Inc. (ABEO) is profitable, generating $82.3M in net income for fiscal year 2024 (20587.5% net margin).
Abeona Therapeutics Inc. (ABEO) has a return on equity (ROE) of -216.6%. Negative ROE indicates the company is unprofitable.
Abeona Therapeutics Inc. (ABEO) had negative free cash flow of $82.4M in fiscal year 2024, likely due to heavy capital investments.